Theragen ETEX Bio Institute said Thursday
that it has signed a memorandum of understanding with My23 Healthcare to
cooperate on expanding its gene analysis services.
Under the agreement, Theragen will provide
its genetic analysis services to My 23 Healthcare, and My23 Healthcare will
focus on sales, marketing and public relations of the service.
Based on Theragen’s genetic analysis
technology, My23 Healthcare will divide the company's 12 direct-to-consumer
(DTC) platforms into three categories for sales. Both companies expect to see
significant synergies between Theragen's differentiated technologies and My 23
healthcare’s sales, marketing and PR capabilities.
“By signing a business
agreement with My23 Healthcare, which has excellent sales, marketing, and PR
capabilities, we have laid the basis for providing genome analysis services to
more customers,” said Theragen ETEX Bio Institute CEO and President Hwang
Tae-soon. “By making gene analysis services more popular, the company will be
able to provide higher quality services, which will greatly contribute to the
national economy as well as promoting public health in the long term.”
My23 Healthcare also showed confidence in
the newly signed MOU.
“Based on the
excellent gene analysis technology of Theragen ETEX, anyone can easily use its
gene analysis services through My23's online service platform,” My23 Healthcare
CEO Hahm Si-won said. “With the collaboration, we will popularize gene analysis
services and contribute to accelerating the alpha-aging era.”
Theragen ETEX Bio Institute is one of the
leading domestic companies. Some of Theragen’s most significant feats include
becoming the first Korean company to succeed in analyzing individual genomes
and identifying Korean gastric cancer gene.
